Clinical Trials Browser

Phase 1 × INDUSTRY × magrolimab × Clear all

NCT06532344 2024-11-14

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Phase 1 Active not recruiting

Gastrointestinal

Unresectable Colorectal Cancer

NCT03558139 2024-04-01

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Phase 1 Completed

34 enrolled 17 charts

Ovarian Neoplasms

NCT03527147 2022-08-15

PRISM

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03922477 2022-02-21

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

13 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02678338 2019-02-21

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02216409 2019-02-05

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Phase 1 Completed

Other solid neoplasm

Solid Tumor